Ashita Waterston

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021 · 364 citations · Full text

Surgical Oncology, Medicine, Melanoma +8

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

Timothy Iveson, Rachel Kerr, Mark Saunders et al. · The Lancet Oncology · 2018 · 183 citations · Full text

Therapeutic antibodies elicited by immunization against TNF-α

Iben Dalum, Debra M. Butler, Martin Roland Jensen et al. · Nature Biotechnology · 1999 · 125 citations

Immune Regulation, Immunology, Antibody Screening +8

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study

Pippa Corrie, Andrea Marshall, Janet Dunn et al. · The Lancet Oncology · 2014 · 109 citations · Full text

Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)

Paul Nathan, Paolo A. Ascierto, John B.A.G. Haanen et al. · European Journal of Cancer · 2019 · 97 citations · Full text

Translational Medicine, Medicine, Melanoma +9